CAR-T therapy, short for "chimeric antigen receptor T-cell" therapy, is revolutionising cancer treatment by reprogramming a patient’s own immune cells to fight their cancer. This innovative approach involves modifying T-cells in a lab to better recognise and attack cancer cells, then infusing them back into the patient.

Recent FDA investigations are looking into potential risks of secondary cancers, with 33 cases documented among around 30,000 treated patients. Despite these concerns, CAR-T therapy continues to offer hope, especially for those with difficult-to-treat lymphomas.

Find out more